Stock Taper
SCREENER COMPARE ANY 2 STOCKS
DMRA
DAMORA THERAPEUTICS, INC.
NASDAQ
$29.00
▼ DOWN 5.23% (-1.60)

KEY STATISTICS

Market Cap$1.79 B
52w High$38.33
52w Low$2.45
Dividend Yield—
Frequency—
P/E-3.29
Volume371.72K
Shares Out.61.55M

COMPANY

LEADERSHIP

Jennifer A. Jarrett
CHIEF EXECUTIVE
Jennifer A. Jarrett

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 29, 2020
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
7

PRICE TARGET

Target High$50.00
Target Low$40.00
Target Median$42.50
Target Consensus$43.75

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.—
NOV
5
THU

PRICE

$29.00 ▼ DOWN 5.23% (−$1.60)
$28.50$29.25$30.00$30.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM29.00

About Damora Therapeutics, Inc.

https://www.damoratx.com ↗

Galecto, Inc. is a Boston-based clinical-stage biotech developing small molecule therapies targeting galectin-3 and LOXL2 to treat cancer and fibrotic diseases.

INDUSTRY

Biotechnology

A PRODUCT DAMORA THERAPEUTICS, INC. IS KNOWN FOR

DMR-001
DMR-001

DMR-001 is an investigational monoclonal antibody targeting mutant calreticulin to treat myeloproliferative neoplasms like essential thrombocythemia and myelofibrosis, addressing an unmet need for disease-modifying therapies.

COMPETITORS

COMPETITOR
BMY COMPARE
GERN COMPARE
GSK COMPARE
INCY COMPARE
NVS COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
67
LISTED HERE
14
RANKED BY POSITION SIZE
XSU.TO
0.05% · 1.3M
XBI
0.20% · 762.5K
VTWO
0.05% · 299.6K
XRSG.L
0.05% · 48.8K
FFSM
0.07% · 30.7K
RSSL
0.05% · 25.4K
BBC
0.88% · 15.1K
OMFS
0.03% · 2.8K
URTY
0.02% · 2.2K
JDOC
0.38% · 1.2K
WCEO
0.17% · 742
SZNE
0.04% · 332
USUE.DE
0.00% · 185
RESM
0.04% · 90

INSTITUTIONAL OWNERSHIP

SHARES OWNED
66.19%
HOLDERS
54
TOP 12 OF 54 · RANKED BY POSITION SIZE
Fmr LLC
9.0M sh · $234.28M
Fairmount Funds Management LLC
8.7M sh · $225.67M
Avoro Capital Advisors LLC
3.8M sh · $97.98M
Vr Adviser, LLC
3.6M sh · $93.33M
Fcpm Iii Services B.V.
2.4M sh · $63.22M
Ra Capital Management, L.P.
2.4M sh · $62.14M
Viking Global Investors LP
2.3M sh · $59.86M
Bellevue Group AG
2.3M sh · $59.52M
Commodore Capital LP
1.9M sh · $50.22M
Cormorant Asset Management, LP
1.5M sh · $39.5M
Balyasny Asset Management L.P.
1.4M sh · $37.5M
Ah Capital Management, L.L.C.
1.2M sh · $32.02M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
DIRECTOR
Cheng Andrew
Purchase · 30.4K shares
2026-08-12
★
Cheng Andrew
— · —
2026-08-12
★
OFFICER: GENERAL COUNSEL
Winslow Garrett
Sale · 680 shares
2026-07-03
★
OFFICER: GENERAL COUNSEL
Winslow Garrett
Sale · 245 shares
2026-07-06

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OUTPERFORM 1
3 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM HC Wainwright & Co. BUY Guggenheim BUY